Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: freedom-35 who wrote (7883)	10/23/2001 5:06:57 PM
From: Cal Gary	Respond to of 14101

I have good news and bad news: 1. Flames 4 Leafs 1 2. Flames 3 Blues 2 3. BRA slips in timeliness, therefore that bumps us up on the timeliness scales Merck KGaA and Biomira say that, following communications with the United States Food and Drug Administration (FDA), the companies will conduct a single interim analysis of data from the phase III trial for Theratope vaccine, a treatment in development for women with metastatic breast cancer. The analysis is expected to occur in the third quarter of next year and is anticipated to be the only interim analysis performed in connection with this study. It will be followed, if necessary, with a final analysis toward the end of 2003. Theratope vaccine has fast-track designation with the FDA. 4. Market Cap comparison; currently in 5th position out of 8. Should also do a comparison between lead product and target market size. 23-Oct Mkt Cap Jr. Bio Shrs O/S Price Market Cap Rank ANP 15,383,356 70.85 1,089,910,773 1 BRA 49,968,600 6.73 336,288,678 3 DMX 42,388,090 4.4 186,507,596 5 HML 39,456,495 7.78 306,971,531 4 LOR 140,247,667 1.08 151,467,480 6 ONC 17,489,037 7.15 125,046,615 7 VAS 44,829,501 8.02 359,532,598 2 WAR 15,676,500 1.1 17,244,150 8 BCH (SHQ) 57 - mid may SHQ 72.58 - QLT 67,739,621 37.15 2,516,526,920